论文部分内容阅读
目的检测乳腺浸润性导管癌患者血清miR-21的表达水平并探讨其临床意义。方法选取自2012年3月~2013年7月于笔者医院就诊乳腺疾病女性患者共49例作为研究对象,其中乳腺良性肿瘤组23例,乳腺浸润性导管癌组26例(Ⅰ期9例、Ⅱ期11例、Ⅲ期6例),应用实时荧光定量(qRT)-PCR检测血清中miR-21的表达水平,并分析血清miR-21的表达与乳腺浸润性导管癌临床病理因素之间的关系。结果乳腺浸润性导管癌组检测的血清miR-21浓度明显高于乳腺良性肿瘤组,血清miR-21的表达增高与TNM分期、淋巴结转移呈正相关。结论血清miR-21在乳腺癌患者血清呈高表达,并与其病理学分级、淋巴结转移密切相关。
Objective To detect the expression of miR-21 in breast invasive ductal carcinoma patients and to investigate its clinical significance. Methods A total of 49 female patients with breast diseases were selected from March 2012 to July 2013 in our hospital. Among them, 23 cases were breast benign tumor and 26 cases were breast invasive ductal carcinoma (stage Ⅰ, stage 9, 11 cases in stage Ⅱ, 6 cases in stage Ⅲ). The expression of miR-21 in serum was detected by qRT-PCR and the relationship between the expression of miR-21 and clinicopathological parameters of invasive ductal carcinoma relationship. Results The serum level of miR-21 in breast invasive ductal carcinoma group was significantly higher than that in benign breast tumor group. The increase of serum miR-21 level was positively correlated with TNM stage and lymph node metastasis. Conclusion Serum miR-21 is highly expressed in the serum of breast cancer patients, and is closely related to its pathological grade and lymph node metastasis.